Incannex (ASX:IHL) share price slips on acquisition news

Investors don't appear to be impressed by the latest update…

| More on:
Man in a cannabis greenhouse looks unhappy and puts his thumb down.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • Incannex has updated the market on a proposed acquisition today
  • Investors don't appear impressed and are selling off Incannex shares instead
  • Incannex shares are up 19% in the past month of trade and have climbed 9% this year to date

The Incannex Healthcare Ltd (ASX: IHL) share price is having a tough time this morning. It sunk 7% from the open before recovering most of its losses and is now 0.71% in the red at 69.5 cents.

Investors are pushing Incannex shares lower after the company announced an acquisition deal.

Despite its shares taking a hit today, the medicinal cannabis company is still in the green across all major time frames, having climbed more than 235% in the past year.

TradingView Chart

What's impacting the Incannex share price?

The Incannex share price is slipping after the company advised it had executed a term sheet to wholly acquire APIRx Pharmaceutical USA, LLC on a proposed all-scrip transaction price of US$93.3 million.

Incannex says APIRx is "an innovative biotechnology company focused on research, development, and production of prescription pharmaceutical cannabinoid medicines".

It has 22 active clinical and preclinical research and development projects utilising its own proprietary technologies, the company added.

For Incannex, the acquisition is set to diversify its portfolio and give the company exposure to a wider array of markets, from pain to dementia to addiction disorders, just to name a few.

As a result, the company claims it now has an expanded total addressable market (TAM) of more than US$400 billion annually.

APIRx can also vote to have one board member designated to Incannex's board after the transaction is completed.

Speaking on the proposed acquisition that might be affecting the Incannex share price today, CEO Joel Latham said:

We believe that bringing together Incannex and APIRx will bolster our position as a leader in the medicinal cannabinoid sector and will further set IHL apart from other players in the industry.

With sizeable addressable markets and intellectual property spanning a multitude of unmet medical needs, we're positioning Incannex to be a significant player in the pharmaceutical sectors of the future. I'm excited by this acquisition opportunity on multiple fronts and look forward to working with the APIRx team to deliver on our vision of providing treatments which will make genuine differences to the lives of millions of people.

What's next?

All the necessary steps are underway to get the transaction underway, but shareholder approval is needed first.

The company will hold an extraordinary general meeting to discuss the transaction and attempt to garner shareholder support.

Incannex will update the market on when this meeting will take place. It also provided some high-level cost estimates.

"Incannex anticipates budgeting approximately A$5.0 million of expenditure on the APIRx product suite in the first 12 months," it said.

"However, the budget may be re-assessed to up to A$10 million following the conclusion, in April, of the Loyalty Option Offer, that could raise up to approximately A$28 million in development capital for the company."

The Incannex share price is up 19% in the past month of trade and has climbed 9% this year to date.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Mergers & Acquisitions

a woman drawing image on wall of big fish about to eat a small fish
Mergers & Acquisitions

Guess which ASX 300 share just received a takeover offer

This share is jumping today after receiving a takeover offer.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Mergers & Acquisitions

Johns Lyng Group shares enter trading halt. Is it a takeover target?

This ASX 200 stock looks ripe for a takeover.

Read more »

Group of people in a gym high five each other surrounded by gym equipment.
Mergers & Acquisitions

This ASX tech stock is hitting a record high on acquisition news

The market is responding positively to this news. Let's dig deeper into it.

Read more »

Two people shaking hands in the boardroom on a merger.
Mergers & Acquisitions

What did Macquarie make of the Brickworks and Soul Patts merger?

Macquarie sees simplification, scale, and upside… but it also has a warning..

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Mergers & Acquisitions

PointsBet share price surges 11% on improved takeover offer

The bidding war for PointsBet shares continues apace today.

Read more »

A couple sit in front of a laptop reading ASX shares news articles and learning about ASX 200 bargain buys
Share Gainers

Why are Soul Patts shares up 9% today?

A marriage proposal has seen investors flock to this company.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Mergers & Acquisitions

Why are Brickworks shares up 18% today?

Let's find out what is getting investors excited this morning.

Read more »

Two hands being shaken symbolising a deal.
Mergers & Acquisitions

Soul Patts to merge with Brickworks shares: What does this mean for investors?

These two blue chips are merging as part of a $14 billion deal.

Read more »